N-(3-metoksy-5-metylpyrazin-2-yl)-2-(4-[1,3,4-oksadiazol-2-yl]fenyl)pyridin-3-sulfonamid, eller et farmasoytisk akseptabelt salt av denne, til behandling av kreft

Det blir beskrevet anvendelse av forbindelsen N-(3-metoksy-5-metylpyrazin-2-yl)-2-(4-[1,3,4-oksadiazol-2-yl]fenyl)pyridin-3-sulfonamid, eller et farmasøytisk akseptabelt salt av denne, i behandling av kreft og/eller smerte i et varmblodig dyr, som menneske. The use of N -(3-methoxy-5-methylpyrazin-2...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	ASHFORD MARIANNE, HUGHES ANDREW MARK, TAYLOR SIAN TOMIKO, BARRASS NIGEL CHARLES, BOYLE FRANCIS THOMAS, TONGE DAVID WILLIAM, JOHNSTONE DONNA
Format:	Patent
Sprache:	nor
Schlagworte:	CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page
container_issue
container_start_page
container_title
container_volume
creator	ASHFORD MARIANNE HUGHES ANDREW MARK TAYLOR SIAN TOMIKO BARRASS NIGEL CHARLES BOYLE FRANCIS THOMAS TONGE DAVID WILLIAM JOHNSTONE DONNA
description	Det blir beskrevet anvendelse av forbindelsen N-(3-metoksy-5-metylpyrazin-2-yl)-2-(4-[1,3,4-oksadiazol-2-yl]fenyl)pyridin-3-sulfonamid, eller et farmasøytisk akseptabelt salt av denne, i behandling av kreft og/eller smerte i et varmblodig dyr, som menneske. The use of N -(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, in the treatment of cancer and/or pain in a warm blooded animal such as man is described.
format	Patent
fullrecord	<record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_NO330756BB1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>NO330756BB1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_NO330756BB13</originalsourceid><addsrcrecordid>eNqNykFuwjAQBdBsWKDSO8wySBkJMCl7KhAruukOVdGAx9TKxI5ig2SO05PWqThAN_9_6b9p8XPEUmHH0bchYT2uJH0a6GEdrjDJPGe5xtOyUtUasyJt6eHl7_wy7DLJ3ursFYabGO-os7oCFuEBOIKhoaPgU7ShBWoD95HOLBEC5aA7aHaOK4hW4Mzf5LRYdx2PdmATZ8XEkAR-ffZLAfvd5_sBufcNh54u7Dg2xw-lFpv6bbtdqn-QX6Q0Uoc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>N-(3-metoksy-5-metylpyrazin-2-yl)-2-(4-[1,3,4-oksadiazol-2-yl]fenyl)pyridin-3-sulfonamid, eller et farmasoytisk akseptabelt salt av denne, til behandling av kreft</title><source>esp@cenet</source><creator>ASHFORD MARIANNE ; HUGHES ANDREW MARK ; TAYLOR SIAN TOMIKO ; BARRASS NIGEL CHARLES ; BOYLE FRANCIS THOMAS ; TONGE DAVID WILLIAM ; JOHNSTONE DONNA</creator><creatorcontrib>ASHFORD MARIANNE ; HUGHES ANDREW MARK ; TAYLOR SIAN TOMIKO ; BARRASS NIGEL CHARLES ; BOYLE FRANCIS THOMAS ; TONGE DAVID WILLIAM ; JOHNSTONE DONNA</creatorcontrib><description>Det blir beskrevet anvendelse av forbindelsen N-(3-metoksy-5-metylpyrazin-2-yl)-2-(4-[1,3,4-oksadiazol-2-yl]fenyl)pyridin-3-sulfonamid, eller et farmasøytisk akseptabelt salt av denne, i behandling av kreft og/eller smerte i et varmblodig dyr, som menneske. The use of N -(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, in the treatment of cancer and/or pain in a warm blooded animal such as man is described.</description><language>nor</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2011</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20110704&DB=EPODOC&CC=NO&NR=330756B1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76290</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20110704&DB=EPODOC&CC=NO&NR=330756B1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>ASHFORD MARIANNE</creatorcontrib><creatorcontrib>HUGHES ANDREW MARK</creatorcontrib><creatorcontrib>TAYLOR SIAN TOMIKO</creatorcontrib><creatorcontrib>BARRASS NIGEL CHARLES</creatorcontrib><creatorcontrib>BOYLE FRANCIS THOMAS</creatorcontrib><creatorcontrib>TONGE DAVID WILLIAM</creatorcontrib><creatorcontrib>JOHNSTONE DONNA</creatorcontrib><title>N-(3-metoksy-5-metylpyrazin-2-yl)-2-(4-[1,3,4-oksadiazol-2-yl]fenyl)pyridin-3-sulfonamid, eller et farmasoytisk akseptabelt salt av denne, til behandling av kreft</title><description>Det blir beskrevet anvendelse av forbindelsen N-(3-metoksy-5-metylpyrazin-2-yl)-2-(4-[1,3,4-oksadiazol-2-yl]fenyl)pyridin-3-sulfonamid, eller et farmasøytisk akseptabelt salt av denne, i behandling av kreft og/eller smerte i et varmblodig dyr, som menneske. The use of N -(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, in the treatment of cancer and/or pain in a warm blooded animal such as man is described.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2011</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNykFuwjAQBdBsWKDSO8wySBkJMCl7KhAruukOVdGAx9TKxI5ig2SO05PWqThAN_9_6b9p8XPEUmHH0bchYT2uJH0a6GEdrjDJPGe5xtOyUtUasyJt6eHl7_wy7DLJ3ursFYabGO-os7oCFuEBOIKhoaPgU7ShBWoD95HOLBEC5aA7aHaOK4hW4Mzf5LRYdx2PdmATZ8XEkAR-ffZLAfvd5_sBufcNh54u7Dg2xw-lFpv6bbtdqn-QX6Q0Uoc</recordid><startdate>20110704</startdate><enddate>20110704</enddate><creator>ASHFORD MARIANNE</creator><creator>HUGHES ANDREW MARK</creator><creator>TAYLOR SIAN TOMIKO</creator><creator>BARRASS NIGEL CHARLES</creator><creator>BOYLE FRANCIS THOMAS</creator><creator>TONGE DAVID WILLIAM</creator><creator>JOHNSTONE DONNA</creator><scope>EVB</scope></search><sort><creationdate>20110704</creationdate><title>N-(3-metoksy-5-metylpyrazin-2-yl)-2-(4-[1,3,4-oksadiazol-2-yl]fenyl)pyridin-3-sulfonamid, eller et farmasoytisk akseptabelt salt av denne, til behandling av kreft</title><author>ASHFORD MARIANNE ; HUGHES ANDREW MARK ; TAYLOR SIAN TOMIKO ; BARRASS NIGEL CHARLES ; BOYLE FRANCIS THOMAS ; TONGE DAVID WILLIAM ; JOHNSTONE DONNA</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_NO330756BB13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>nor</language><creationdate>2011</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>ASHFORD MARIANNE</creatorcontrib><creatorcontrib>HUGHES ANDREW MARK</creatorcontrib><creatorcontrib>TAYLOR SIAN TOMIKO</creatorcontrib><creatorcontrib>BARRASS NIGEL CHARLES</creatorcontrib><creatorcontrib>BOYLE FRANCIS THOMAS</creatorcontrib><creatorcontrib>TONGE DAVID WILLIAM</creatorcontrib><creatorcontrib>JOHNSTONE DONNA</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>ASHFORD MARIANNE</au><au>HUGHES ANDREW MARK</au><au>TAYLOR SIAN TOMIKO</au><au>BARRASS NIGEL CHARLES</au><au>BOYLE FRANCIS THOMAS</au><au>TONGE DAVID WILLIAM</au><au>JOHNSTONE DONNA</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>N-(3-metoksy-5-metylpyrazin-2-yl)-2-(4-[1,3,4-oksadiazol-2-yl]fenyl)pyridin-3-sulfonamid, eller et farmasoytisk akseptabelt salt av denne, til behandling av kreft</title><date>2011-07-04</date><risdate>2011</risdate><abstract>Det blir beskrevet anvendelse av forbindelsen N-(3-metoksy-5-metylpyrazin-2-yl)-2-(4-[1,3,4-oksadiazol-2-yl]fenyl)pyridin-3-sulfonamid, eller et farmasøytisk akseptabelt salt av denne, i behandling av kreft og/eller smerte i et varmblodig dyr, som menneske. The use of N -(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, in the treatment of cancer and/or pain in a warm blooded animal such as man is described.</abstract><oa>free_for_read</oa></addata></record>
fulltext	fulltext_linktorsrc
identifier
ispartof
issn
language	nor
recordid	cdi_epo_espacenet_NO330756BB1
source	esp@cenet
subjects	CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title	N-(3-metoksy-5-metylpyrazin-2-yl)-2-(4-[1,3,4-oksadiazol-2-yl]fenyl)pyridin-3-sulfonamid, eller et farmasoytisk akseptabelt salt av denne, til behandling av kreft
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T09%3A19%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=ASHFORD%20MARIANNE&rft.date=2011-07-04&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ENO330756BB1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true